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Background: Neuronal iron accumulation is thought to be relevant to the pathogenesis of Parkinson’s dis-
ease (PD), although the mechanism remains elusive. We hypothesized that neuronal iron uptake may be
stimulated by functional mitochondrial iron deﬁciency.
Objective: To determine ﬁrstly whether the mitochondrial toxin, 1-methyl-4-phenylpyridinium iodide
(MPP+), results in upregulation of iron-import proteins and transporters of iron into the mitochondria,
and secondly whether similar changes in expression are induced by toxins with different mechanisms
of action.
Methods: We used quantitative PCR and Western blotting to investigate expression of the iron importers,
divalent metal transporter, transferrin receptor 1 and 2 (TfR1 and TfR2) and mitoferrin-2 and the iron
exporter ferroportin in differentiated SH-SY5Y cells exposed to three different toxins relevant to PD,
MPP+, paraquat (a free radical generator) and lactacystin (an inhibitor of the ubiquitin–proteasome sys-
tem (UPS)).
Results: MPP+ resulted in increased mRNA and protein levels of genes involved in cellular iron import and
transport into the mitochondria. Similar changes occurred following exposure to paraquat, another indu-
cer of oxidative stress. Lactacystin also resulted in increased TfR1 mRNA levels, although the other
changes were not found.
Conclusion: Our results support the hypothesis of a functional mitochondrial iron deﬁcit driving neuronal
iron uptake but also suggest that differences exist in neuronal iron handling induced by different toxins.
 2011 Elsevier B.V. All rights reserved.1. Introduction
Increase in intraneuronal iron is thought to be relevant to the
pathogenesis of Parkinson’s disease (PD) (Kaur and Andersen,
2004); The mechanism remains elusive but may involve changes
in expression of iron transport proteins, including the iron import-
ers, divalent metal transporter (DMT1) (Lee et al., 1998), transfer-
rin receptor 1 (TfR1), transferrin receptor 2 (TfR2), possiblyll rights reserved.
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Oliver.hanemann@pms.ac.ukresponsible for transporting transferrin-bound iron into mitochon-
dria (Mastroberardino et al., 2009), and mitoferrin-2 (Mfrn2), a
protein involved in mitochondrial iron uptake in non-erythroid
cells (Richardson et al., 2010), and the exporter ferroportin (FPN)
(Abboud and Haile, 2000). DMT1 has two isoforms, one with an
iron-response element (IRE), DMT1 (+IRE), and one without,
DMT1 (IRE).
A variety of toxin-based cell culturemodels of PDmimic the var-
ious abnormalities that have been implicated in the pathogenesis of
PD: 1-methyl-4-phenylpyridinium iodide (MPP+) inhibits mito-
chondrial function (Kalivendi et al., 2004, 2003); paraquat is a free
radical generator (Dinis-Oliveira et al., 2006); and lactacystin is a
potent and speciﬁc inhibitor of the ubiquitin proteasome system
(UPS) (Zhang et al., 2005). The protective effects of iron chelation
against each of these toxins has been demonstrated in a variety of
models (Ayaki et al., 2005; Molina-Holgado et al., 2008; Santiago
et al., 1997; Xu et al., 2008; Zhang et al., 2005; Zhu et al., 2007).
Oxidative damage to mitochondrial iron–sulphur clusters may
result in mitochondrial functional iron deﬁcit thereby acting as a
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2009; Paradkar et al., 2009). Previous studies in rat cerebellar gran-
ule cells and human neuroblastoma cells have demonstrated an in-
crease in TfR1 protein expression following exposure to MPP+
(Kalivendi et al., 2003). Postmortem studies have demonstrated in-
creased [125I]Tf(Fe)2 binding in the striatum of PD patients (Fauc-
heux et al., 1995). There is increased expression of DMT1 (+IRE)
in C6 cells treated with 6-hydroxydopamine (6-OHDA) at both
the protein and mRNA level (Song et al., 2007) and increased pro-
tein in the ventral mesencephalon of MPTP-treated mice (Salazar
et al., 2008). However, these ﬁnding contrasts with those in a mur-
ine cell line exposed to MPP+ (Zhang et al., 2008). Increased expres-
sion of DMT1 (+IRE) protein has also been found in human
parkinsonian nigra (Salazar et al., 2008). There is a reduction in
FPN protein and mRNA levels in the substantia nigra of 6-OHDA-
treated rats (Wang et al., 2007a). Additionally it has been shown
that in nigral dopaminergic cells of rotenone-treated rats there
are increased levels of transferrin and TfR2 (Mastroberardino
et al., 2009).
Although partially conﬂicting and incomplete, these data sug-
gest that altered expression of genes involved in neuronal iron
homeostasis occurs in sporadic PD and in animal and cell culture
models, and that regulation may occur at the transcriptional level.
Here we systematically investigate expression of DMT1, TfR1, TfR2,
Mfrn2 and FPN in a human cell culture model using three different
toxins relevant to PD and demonstrate upregulation of the iron
importers in response to MPP+ and paraquat, supporting the
hypothesis of mitochondrial functional iron deﬁcit stimulating iron
uptake under conditions of oxidative stress.2. Materials and methods
2.1. Materials
Unless otherwise stated, all chemicals were purchased from Sig-
ma Aldrich Chemicals, Dorset, UK. Dulbecco’s modiﬁed Eagle’s
medium was purchased from Invitrogen (Paisley, UK).2.2. Culture of neuroblastoma cells
Human neuroblastoma cells (SH-SY5Y) were obtained from
ECACC, transferred to 75 cm2 ﬁlter vent ﬂasks (VWR, Leicester-
shire, UK)), grown in Dulbecco’s modiﬁed Eagle’s medium contain-
ing 10% (v/v) fetal bovine serum (FBS) (PAA, Yeovil, UK), glutamine,
4.5 g/l glucose, supplemented with 1 ml uridine (25 mg/ml), 5 ml
pyruvate, 25 units/ml penicillin and 25 lg/ml streptomycin, and
incubated at 37 C in a humidiﬁed atmosphere of 5% CO2 and
95% air. For experiments, cells were seeded in 6-well dishes
(VWR) (200,000 cells/well) or 96-well plates (VWR) (10,000 cells/
well) and treated with 10 lM retinoic acid for 5–7 days to promote
differentiation to a neuronal phenotype. Medium was changed
every 48 h.2.3. Cell treatments
2.3.1. Toxin administration
After differentiation toxins were added to the cell culture med-
ium in addition to the retinoic acid. Concentrations of toxin were
chosen that resulted in about 2–3 fold cell death at 48 h compared
with vehicle: 5–7 mM 1-methyl-4-phenylpyridinium iodide
(MPP+), 20 lM lactacystin (Merck, Nottingham, UK) and 300–
500 lM paraquat (Supplementary Fig. 1).2.4. LDH-release assay
To assess the cytotoxicity of the toxins under our experimental
conditions, LDH release was measured in treated cells grown in 96-
well plates. Cell culture medium (50 ll) was used to analyze the
LDH activity by measuring the oxidation of NADH at 450 nm as de-
scribed in the manufacturer’s protocol (Promega). The remaining
cells were lysed and LDH activity similarly measured to allow
the percentage of cell death to be calculated. Each assay was per-
formed a minimum of six times in quadruplicate.
2.5. Measurement of reactive oxygen species
SH-SY5Y cells were seeded into 96 well plates. After 48 h of
treatment with MPP+, lactacystin and paraquat (for 6, 12, 24 and
48 h), medium was removed and cells were incubated with
10 lM 20,70-Dichlorodihydroﬂuorescein diacetate (DCFDA) (Sig-
ma–Aldrich) in medium for 30 min. Cells were then washed three
times with PBS after which the ﬂuorescence was measured at
Ex:485 nm and Em:535 nm. The LDH assay was used to determine
the proportion of surviving cells. Each assay was performed with a
minimum of eight repeats on two separate occasions. Statistical
signiﬁcance was determined using one-way analysis of variance
in SPSS.
2.6. Total RNA extraction and quantitative PCR
Total RNA was extracted using GenElute (Sigma–Aldrich) and
treated with DNA-free (Ambion, Huntingdon, UK) according to
the manufacturers’ instructions. Total RNA was reverse transcribed
in a 50 ll reaction using cDNA Archive Kit (Ambion). Quantitative
PCR was employed to detect changes of ferroportin, TfR1, TfR2,
Mfrn2 and DMT+/ IRE. (FAM)-labeled TfR2 (Hs00162690_m1)
and Mfrn2 (Hs00377907_m1) primers were purchased from Ap-
plied Biosystems (Warrington, Cheshire, UK). Primers for the
remaining sequences were designed using Roche Universal ProbeL-
ibrary Assay Design (Roche). In this system probes are labeled 50-
terminal with ﬂuorescein (FAM) and 30-proximal with a dark
quencher dye. The following primers and probes were used:
DMT1 (+IRE) forward 50-catgcccaagatgacttgc-30, reverse 50-
tgtgctttgcaacggttaag-30, probe 17; DMT (IRE) forward 50-ac-
ctctacctccccggttta-30, reverse 50-ccccatctccactaaaaatgtg-30, probe
63; ferroportin forward 50-catgtaccatggatgggttct-30, reverse 50-
caatatttgcaatagtgatgatcagg-30, probe 4; TfR1 forward 50-ttgagaaaa-
caatgcaaaatgtg-30, reverse 50-cccagttgctgtcctgatataga-30, probe 61.
Reactions were carried out on a Biorad ICycler. Each reaction was
run in triplicate with 1 ll sample in a total volume of 20 ll. Ampli-
ﬁcation and detection were performed with the following condi-
tions: an initial hold at 95 C for 10 s followed by 50 cycles at
95 C for 15 s and 60 C for 60 s. Gene expression was normalized
to 18 s expression run in triplicate concurrently. All samples were
analyzed in triplicate on triplicate samples from four separate
experiments. Statistical signiﬁcance was determined using one-
way analysis of variance in SPSS.
2.7. Protein extraction and Western blot analysis of protein levels
Cells were lysed for protein extraction at 6, 12, 24 and 48 h fol-
lowing exposure to the toxins. Cells were washed with ice-cold PBS
and protein extracted with NET-Triton buffer (150 mM NaCl, 5 mM
EDTA (ethylenediaminetetraacetic acid), 10 mM Tris (tris(hydroxy-
methyl)aminomethane), pH 7.4, 1% Triton X-100) supplemented
with protease inhibitor cocktail (Sigma–Aldrich) according to the
manufacturer’s instructions. Protein level was estimated using
the bicinchoninic acid (BCA) assay. 20 lg was loaded into each well
for Western blotting.
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onto PVDF membranes. Membranes were washed with Tris-buf-
fered saline (140 mM NaCl, 50 mM tris/HCl, pH7.2) containing
0.1% Tween 20, 5% skimmed milk and 2% BSA to block the non-spe-
ciﬁc protein binding. Membranes were incubated with primary
antibody against TfR1 (abcam, Cambridge UK, ab65831), TfR2 (ab-
cam ab84287), DMT1 (both isoforms) (Autogen Bioclear, Wiltshire,
UK NRAMP-22A), Mfrn2 (abcam, Cambridge UK, ab74681) and FPN
(antibody kind gift from David Haile) in Tris-buffered saline
(140 mM NaCl, 50 mM tris/HCl, pH7.2) containing 0.1% Tween 20,
5% skimmedmilk and 2% BSA overnight at 4 C, washed three times
and then incubated with horseradish-peroxidase-conjugated sec-
ondary antibody for 1 h at room temperature. To correct for varia-
tion in protein levels, the same membrane was probed with rabbit
anti-human b-actin antibody (abcam) at a 1:5000 dilution. The
protein bands were detected using the ECL method (Amersham
Biosciences, Little Chafont, Buckinghamshire, UK) and then ana-
lyzed through scanning densitometry by a BioRad Fluor-S MultiIm-
ager. Results are based on a mean of a minimum of six different
samples. Statistical signiﬁcance was determined using one-way
analysis of variance in SPSS.3. Results
3.1. Changes in gene and protein expression
We found that MPP+ resulted in a signiﬁcant increase in mRNA
levels for the iron import proteins, TfR1 and DMT1 (+IRE) as well as
the presumed mitochondrial iron transporters, TfR2 and Mfrn2.
(Fig. 1). We found a non-signiﬁcant increase in the level of mRNA
for the iron export protein FPN (p = 0.051). In addition there was
a 10 fold reduction in mRNA level for DMT1 (IRE). The changes
observed were largely paralleled by changes in protein expression
with the exception of DMT, where no signiﬁcant change in expres-
sion was observed, probably due to the antibody recognizing both
isoforms of DMT. In addition protein levels of mitoferrin-2 reduced
signiﬁcantly over 48 h in contrast to the increase in mRNA. Finally
we demonstrated increased levels of transferrin into MPP+-treated
cells over 48 h, although this failed to reach signiﬁcance (Fig. 1f).
We were interested to see whether similar changes in mRNA
occurred with another free-radical generating toxin, paraquat,
and found similar changes in both isoforms of DMT and TfR1, with
more modest but signiﬁcant upregulation of TfR2 and Mfrn2; in
addition there was a slight reduction in mRNA for FPN (Fig. 2). Sim-
ilar changes in protein expression to those following MPP+ were
also observed. However, while MPP+ treatment resulted in a signif-
icant increase in TfR1 and TfR2 protein expression at 48 h, protein
levels peaked at 12 h of treatment with PQT. The most notable dif-
ference between MPP+ and PQT treatment was a marked reduction
in mitoferrin-2 expression following 12 h exposure to PQT with
recovery at 24 and 48 h.
In order to investigate whether similar changes occurred with a
toxin used to model PD with a different mechanism of action, dif-
ferentiated cells were exposed to lactacystin, a potent and speciﬁc
inhibitor of the UPS. This resulted in a signiﬁcant reduction in
mRNA level for all the proteins investigated within either 12 or
24 h, with the exception of mitoferrin-2, although there was a sig-
niﬁcant 1.8 fold increase in TfR1 mRNA at 48 h (Fig. 3). Western
blotting revealed no change in total DMT and an increase in Mfrn2
and FPN at 48 h. There was no increase in transferrin.
Finally to determine whether the differences observed between
the responses to the toxins could be explained by different degrees
of oxidative stress induced we measured ROS using the DCFDA as-
say, which primarily measures hydrogen peroxide production. This
demonstrated a signiﬁcant increase in ROS with all three toxinscompared with vehicle, although it was much greater with MPP+
than with paraquat or lactacystin (Fig. 4).4. Discussion
In this study we investigated MPP+, a toxin associated with oxi-
dative stress in a human cell culture model to mimic PD, and dem-
onstrated expression change of proteins involved in neuronal iron
import and transport of iron into mitochondria. These ﬁndings
support those of studies involving animal models or rodent cell
lines in which increased expression of DMT1 (+IRE) (Salazar
et al., 2008), TfR1 (Kalivendi et al., 2003; Shang et al., 2004) and
TfR2 (Mastroberardino et al., 2009) have been demonstrated fol-
lowing exposure to mitochondrial inhibitors, MPP+ or rotenone.
Although we have demonstrated changes in iron regulatory pro-
teins in our study, we do not know whether this translates into
an actual change in cellular iron content. Nevertheless our system-
atic data on the mechanism of iron import support the hypothesis
that mitochondrial functional iron deﬁcit acts as a stimulus for iron
import, which may result in neuronal iron overload and contribute
to neuronal death.
MPP+ is an inhibitor of complex I, resulting in production of
reactive oxygen species (Fiskum et al., 2003; Hartley et al., 1994;
Przedborski and Vila, 2003), which are known to cause oxidation
of thiols in cysteine residues (Mastroberardino et al., 2009) and
carbonylation of complex I itself (Keeney et al., 2006). We demon-
strated intracellular production of hydrogen peroxide following
MPP+ exposure using the DCFDA assay, suggestive of mitochondrial
dysfunction. Although maximal levels of ROS were seen at 48 h, it
is likely that mitochondrial dysfunction occurred at earlier time
points, resultant radical production being ameliorated by intracel-
lular quenchers. It has been suggested that oxidation of Fe–S clus-
ters within mitochondrial proteins results in impaired utilization
of iron (Mastroberardino et al., 2009). We hypothesized that the
mitochondrial functional iron deﬁciency induced by MPP+ would
result in upregulation of iron-import proteins and transporters of
iron into the mitochondria, as has been suggested to occur in ery-
throid and non-erythroid cells following inhibition of heme syn-
thesis or frataxin-deletion (Paradkar et al., 2009; Richardson
et al., 2010). Our ﬁnding of increased TfR1, DMT1 (+IRE), TfR2
and Mfrn2 mRNA levels following MPP+ exposure, largely paral-
leled by protein levels and increase in transferrin supports this
hypothesis. Interestingly we found a marked reduction in mitofer-
rin-2 protein level following MPP+ exposure. It is likely that this
reduction results in persistently reduced mitochondrial iron deliv-
ery even in the presence of increased cytosolic iron (Paradkar et al.,
2009), thereby perpetuating mitochondrial dysfunction. Although
it has been well demonstrated that many factors inﬂuence the cor-
relation between measured mRNA and protein levels (Guo et al.,
2008; Maier et al., 2009), the divergent results of mRNA and pro-
tein levels of mitoferrin-2 raise interesting questions about the
regulation of mitoferrin-2 expression, which is as yet poorly under-
stood. One possibility is regulation of protein degradation resulting
in altered half-life as has been suggested for mitoferrin-1 in ery-
throid cells (Paradkar et al., 2009).
We predicted that similar changes in expression of these genes
and proteins would result after exposure to other toxins associated
with oxidative stress, such as paraquat, and demonstrated that this
was the case. Paraquat acts as a free radical generator (Ayaki et al.,
2005; Dinis-Oliveira et al., 2006) and has been demonstrated to re-
sult in apoptosis in SH-SY5Y cells (Gonzalez-Polo et al., 2007a,b).
One mechanism by which the mRNA changes may occur is in-
creased binding of iron response proteins (IRPs) to the 30UTR IREs
of TfR1 and DMT1 (+IRE), increasing the cytoplasmic stability of
the transcripts (Mullner and Kuhn, 1988; Mullner et al., 1989).
Fig. 1. Exposure of differentiated SH-SY5Y cells to MPP+ resulted in a signiﬁcant increase in mRNA levels of TfR1 (a), DMT1 (+IRE) (b), TfR2 (c) and Mfrn2 (d). There was a
signiﬁcant reduction in mRNA level for DMT1 (IRE) (b) and no signiﬁcant change in mRNA for ferroportin (e). These changes were accompanied by similar changes in protein
level, with the exception of total DMT and mitoferrin-2. There was also a non-signiﬁcant increase in transferrin protein level (f) (⁄p < 0.05; ⁄⁄p < 0.005).
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situations of oxidative stress, Fe–S disassembly directs IRP1 back to
its high IRE afﬁnity form (Volz, 2008). It has previously been dem-
onstrated that paraquat increases binding of IRP1 to IREs (Ayaki
et al., 2005). Our ﬁnding of mRNA level for both DMT (+IRE) and
TfR1 being highest at 48 h following exposure to both MPP+ and
paraquat, paralleling the time of maximal ROS production, sup-
ports this hypothesis. However, interestingly, we found increase
in TfR1 protein level at earlier time points following exposure to
both MPP+ and paraquat, suggesting that other mechanisms exist
to control TfR1 protein expression under these conditions. These
may include translational stimulation as has been shown to be
the case following sustained exposure to low levels of hydrogen
peroxide in other cell culture systems (Andriopoulos et al., 2007).In contrast to DMT1 (+IRE), we found a signiﬁcant reduction in
the level of mRNA for the non-IRE isoform of DMT in response to
MPP+ and paraquat. This ﬁnding is consistent with a reduction in
DMT (IRE) protein found in the substantia nigra of PD patients
in a post mortem study (Salazar et al., 2008). This signiﬁcant reduc-
tion in DMT (IRE) mRNA may explain the lower expression of to-
tal DMT protein at the 24 and 48 h time points in MPP+ treated
samples and the unchanged total DMT protein expression in PQT
treated samples. DMT1 (IRE) has been found to localize to the nu-
clei of neurons as well as the cell surface, suggesting that it may
have a role other than iron import in neuronal cells (Roth et al.,
2000). In contrast, DMT1 (+IRE) localizes to the cell surface of neu-
rons as well as within vesicles within dendrites and axons, consis-
tent with a role in iron uptake (Roth et al., 2000). Our ﬁnding that
Fig. 2. A similar pattern of change in mRNA levels was seen following exposure of differentiated SH-SY5Y cells to 300 lM paraquat, with a signiﬁcant increase in mRNA levels
for TfR1 (a), DMT1 (+IRE) (b), TfR2 (c) and Mfrn2 (d), and a signiﬁcant reduction in mRNA level for DMT1 (IRE) (b). There was a modest but signiﬁcant decrease in mRNA for
ferroportin (e) (⁄p < 0.05; ⁄⁄p < 0.005). There were similar changes in protein level, with the exception of total DMT and mitoferrin-2. There was also a non-signiﬁcant increase
in transferrin protein level (f) (⁄p < 0.05; ⁄⁄p < 0.005).
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to toxin exposure supports the notion that they have different
functions in neuronal cells.
TfR2 is thought to act as a transporter of iron into mitochondria
(Mastroberardino et al., 2009). The mRNA sequence of TfR2 does
not contain an IRE, and therefore the mechanism by which levels
are increased remains undetermined. Nevertheless we have dem-
onstrated a signiﬁcant increase in TfR2 mRNA levels following
complex I inhibition with MPP+, and to a lesser extent following
paraquat exposure, paralleled by protein increase, which is in
keeping with a previous demonstration of an increase in nigral
dopaminergic TfR2 protein expression in rotenone-treated rats
(Mastroberardino et al., 2009). It has previously been shown inSH-SY5Y cells that ferroportin protein levels are upregulated in re-
sponse to increasing cellular iron content, and that this is associ-
ated with increased cell survival. (Aguirre et al., 2005) However,
the opposite effect of iron loading has been found in rat PC12 cells
(Chen et al., 2005), implying that there may be important species
and cell type differences in neuronal iron homeostasis. We found
non-signiﬁcant increases in ferroportin mRNA and protein level
after exposure to MPP+, compatible with a protective response to
iron loading. It has been suggested that ferroportin expression is
down-regulated post-transcriptionally via 50-IRP1/IRE interaction
in response to inﬂammatory stimuli (Liu et al., 2002). Oxidative
stress results in increased IRP1 activity and subsequent repression
of mRNA translation (Volz, 2008). Our ﬁnding of a possible change
Fig. 3. Exposure of differentiated SH-SY5Y cells to 20 lM lactacystin resulted in reduced levels of mRNA for all of the proteins investigated other than mitoferrin-2 (d): TfR1
(a), DMT1 (+IRE) (b), DMT1 (IRE) (b), TfR2 (c), and FPN (e). However at 48 h there was a signiﬁcant increase in mRNA level for TfR1 (a). There was a signiﬁcant increase in
mitoferrin-2 and ferroportin protein level at 48 h; otherwise there was no change in protein expression (⁄p < 0.05; ⁄⁄p < 0.005).
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expression at a transcriptional level in addition to these possible
translational mechanisms.
Disruption of the UPS is thought to be relevant not only to some
familial forms of PD, but also to sporadic disease (McNaught et al.,
2003). Lactacystin is a potent and speciﬁc UPS inhibitor which has
been shown to result in ubiquitin and a-synuclein positive aggre-
gates in SH-SY5Y cells (Lev et al., 2006) and has been used to model
PD in animal studies (McNaught et al., 2004). The mechanisms of
action of MPP+ and paraquat have also been suggested to involve
inhibition of the UPS (Domingues et al., 2008; Sun et al., 2007).
However, we found that the pattern of change in mRNA and pro-
tein levels was different following UPS inhibition with lactacystin,
which may reﬂect a lower induction of oxidative stress, although ithas been proposed that lactacystin results in accumulation of oxi-
datively damaged proteins resulting in cell death (Zhang et al.,
2005). We found that lactacystin resulted in an initial reduction
in mRNA levels for all of the proteins investigated other than
Mfrn2, which may represent a down-regulation of transcription
following disruption of normal protein trafﬁcking induced by inhi-
bition of the UPS. We also found increased expression of mitofer-
rin-2 and ferroportin proteins at 48 h, without an associated
change in mRNA, which may reﬂect altered degradation pathways.
However, there was a signiﬁcant increase in mRNA level for TfR1 at
48 h. Previous studies have suggested that IRP2 plays an important
role in controlling TfR1 expression (Kim and Ponka, 1999; Wang
et al., 2007b). It is known that IRP2 is degraded primarily via the
UPS (Iwai et al., 1998; Kim and Ponka, 1999). Lactacystin could
Fig. 4. There was a signiﬁcant increase in ROS production following exposure to all
three toxins, but this was much more marked in response to MPP+ (⁄p < 0.05;
⁄⁄p < 0.005, ⁄⁄⁄p < 0.001).
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ization of mRNA for the TfR1.5. Conclusions
In conclusion we have demonstrated in differentiated human
neuroblastoma cells that the mitochondrial complex I inhibitor,
MPP+, results in expression change for proteins involved in cellular
iron import and transport of iron into the mitochondria, as well as
an increase in transferrin, supportive of the hypothesis of a func-
tional mitochondrial iron deﬁcit driving neuronal iron uptake. Sim-
ilar changes occur following exposure to paraquat, another inducer
of oxidative stress. Although lactacystin, an inhibitor of the UPS,
also resulted in increased TfR1 mRNA levels, the other changes
were not found suggesting that there are signiﬁcant differences
in neuronal iron handling induced by the different toxins.
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